Alcon Inc. (ALC)
| Market Cap | 38.71B |
| Revenue (ttm) | 9.46B |
| Net Income (ttm) | 974.00M |
| Shares Out | 493.30M |
| EPS (ttm) | 1.96 |
| PE Ratio | 40.31 |
| Forward PE | 26.67 |
| Dividend | $0.27 (0.35%) |
| Ex-Dividend Date | May 14, 2024 |
| Volume | 757,057 |
| Open | 79.09 |
| Previous Close | 79.00 |
| Day's Range | 78.28 - 79.26 |
| 52-Week Range | 69.44 - 88.23 |
| Beta | 0.67 |
| Analysts | Strong Buy |
| Price Target | 90.76 (+15.66%) |
| Earnings Date | May 7, 2024 |
About ALC
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic mi... [Read more]
Financial Performance
In 2023, Alcon's revenue was $9.46 billion, an increase of 8.47% compared to the previous year's $8.72 billion. Earnings were $974.00 million, an increase of 190.75%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for ALC stock is "Strong Buy." The 12-month stock price forecast is $90.76, which is an increase of 15.66% from the latest price.
News
Alcon Publishes Agenda for 2024 Annual General Meeting
GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for 2024 Annual General Meeting.
Vivity, the World's Leading EDOF IOL, Reaches One Million Milestone
TORONTO--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended dep...
Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023
GENEVA--(BUSINESS WIRE)--Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023.
Alcon's stock falls as third-quarter sales miss estimates
Alcon Inc. shares ALC, +4.04% dropped more than 4% premarket on Wednesday after the eye care company on Tuesday reported third-quarter revenues below analysts' expectations.
Alcon Reports Third Quarter 2023 Results
GENEVA--(BUSINESS WIRE)--Alcon Reports Third Quarter 2023 Results.
Alcon Reports Second Quarter 2023 Results
GENEVA--(BUSINESS WIRE)--Alcon Reports Second Quarter 2023 Results.
Alcon CEO: Aging population and new technology driving eyecare business forward
David Endicott, CEO at Alcon, discusses first-quarter earnings, and shares his optimism for the business despite macroeconomic pressures.
Alcon Reports First Quarter 2023 Results
GENEVA--(BUSINESS WIRE)--Alcon Reports First Quarter 2023 Results.
Alcon's “The Lens” Interactive Compliance Training Experience Receives Coveted Anthem Award
GENEVA--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that its interactive compliance training video experience, The Lens, has been...
Alcon Reports Fourth Quarter and Full Year 2022 Results
GENEVA--(BUSINESS WIRE)--Alcon Reports Fourth Quarter and Full Year 2022 Results
Alcon Canada launches new TOTAL toric lenses for astigmatic patients
TORONTO--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the Canadian launch of TOTAL30® for Astigmatism and DAILIE...
Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism
GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced plans to launch TOTAL30® for Astigmatism, the first-and-onl...
Alcon to Present at 2023 Annual J.P. Morgan Healthcare Conference
GENEVA--(BUSINESS WIRE)--Regulatory News:
Alcon Prices US$1.3 Billion Senior Notes Offering
GENEVA--(BUSINESS WIRE)--Alcon Inc. ("Alcon") (SIX/NYSE: ALC) announced that it has commenced and priced a private offering of US$700 million aggregate principal amount of its 5.375% senior notes du...
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business
GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceutic...
Alcon Reports Third Quarter 2022 Results
GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine months ended September 30, 2022. For the third quarter of 2022, sa...
Alcon to Celebrate 75 Years of Brilliance and Showcase Contact Lens Innovations at #Academy22
FORT WORTH, Texas--(BUSINESS WIRE)--Alcon to Celebrate 75 Years of Brilliance and Showcase Contact Lens Innovations at #Academy22
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C.
Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022
FORT WORTH, Texas--(BUSINESS WIRE)--Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022
AERIE PHARMACEUTICALS - INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
NEW ORLEANS , Sept. 27, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.
Don't Look for Alcon's Acquisition to Boost Share Price in Short Term
Most investors would probably be pleased with a share price gain of 33% in just over three years, but more than 50% sounds a lot better.
Aerie set to be bought by Alcon for $770 million
New Jersey-based biotech firm Aerie is seeing its shares move higher amid news of it being bought by Aerie Pharmaceuticals.
SHAREHOLDER ALERT: Weiss Law Investigates Aerie Pharmaceuticals, Inc.
NEW YORK , Aug. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aerie Pharmaceuticals, Inc. ("Aerie" or...
Alcon to Acquire Aerie Pharmaceuticals for $15.25 a Share
Alcon agrees to acquire Aerie, the ophthalmic therapies company, for $15.25 a share.
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
GENEVA & DURHAM, N.C.--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI...